Purpose To dissect the tumor ecosystem following immune checkpoint blockades (ICBs) in
intrahepatic cholangiocarcinoma (ICC) at a single-cell level. Methods Single-cell RNA …

Background While there have been encouraging preliminary clinical results for immune
checkpoint inhibitors (ICIs) in BTCs, it remains a challenge to identify the subset of patients …

Background & Aims Cholangiocarcinoma is an aggressive hepatobiliary malignancy
originating from biliary tract epithelium. Whether cholangiocarcinoma is responsive to …

Background and Aims Cholangiocarcinoma (CCA) is a deadly and highly therapy‐refractory
cancer of the bile ducts, with early results from immune checkpoint blockade trials showing …

Background: Cholangiocarcinoma (CCA) encompasses a heterogeneous group of
malignant tumors with dismal prognosis and increasing incidence worldwide. Both late …

Background Immune checkpoint inhibitor (ICI)-combined chemotherapy in advanced
intrahepatic cholangiocarcinoma has been proved to have more efficacy in a series of …

Background: The tumor microenvironment (TME) in cholangiocarcinoma (CCA) influences
the immune environment. Checkpoint blockade is promising, but reliable biomarkers to …

Cholangiocarcinoma (CCA) is a hepatobiliary malignancy associated with steadily
increasing incidence and poor prognosis. Ongoing clinical trials are assessing the …

Immune checkpoint blockade (ICB) has revolutionized cancer therapeutics. Desmoplastic
malignancies, such as cholangiocarcinoma (CCA), have an abundant tumor immune …

Objective Intrahepatic cholangiocarcinoma (ICC) exhibits very low response rate to immune
checkpoint inhibitors (ICIs) and the underlying mechanism is largely unknown. We …